Skip to Main content Skip to Navigation
Journal articles

Efficacy and safety of autologous stem cell transplantation after induction therapy with lenalidomide, bortezomib, and dexamethasone

Abstract : Recently, phase III trials assessed a new combination of lenalidomide, bortezomib, and dexamethasone (RVD) in induction therapy in transplantation‐eligible multiple myeloma (MM) patients, before consolidation with RVD and lenalidomide maintenance. We present a retrospective study evaluating this approach with patients from the real life.
Document type :
Journal articles
Complete list of metadatas

Cited literature [29 references]  Display  Hide  Download

https://hal-amu.archives-ouvertes.fr/hal-02267221
Contributor : Lionel Spinelli <>
Submitted on : Friday, October 18, 2019 - 9:52:29 AM
Last modification on : Wednesday, August 19, 2020 - 12:08:23 PM
Long-term archiving on: : Sunday, January 19, 2020 - 1:05:14 PM

Files

Revised Manuscript VRD EJH Fin...
Files produced by the author(s)

Identifiers

Collections

Citation

Robin Arcani, Geoffroy Venton, Julien Colle, Pierre Suchon, Vadim Ivanov, et al.. Efficacy and safety of autologous stem cell transplantation after induction therapy with lenalidomide, bortezomib, and dexamethasone. European Journal of Haematology, Wiley, 2019, ⟨10.1111/ejh.13297⟩. ⟨hal-02267221⟩

Share

Metrics

Record views

203

Files downloads

390